Literature DB >> 33718940

Recent progress in the treatment of non-systemic juvenile idiopathic arthritis.

John M Bridges1, Elizabeth D Mellins2, Randy Q Cron1.   

Abstract

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease affecting the joints and other organs that occurs in 1 in 1,000 children in the United States. Given the various categories of JIA, interpretation of the literature can be difficult. In this review, new developments in understanding non-systemic JIA and its treatment will be covered. Recent advances in the journey toward personalized treatment in JIA will be highlighted, including a review of currently available biologic modifiers. Uveitis and the temporomandibular joint will be discussed as particularly challenging treatment issues. Recent guideline updates and literature-guided treatment decisions will be reviewed. Copyright:
© 2021 Cron RQ et al.

Entities:  

Keywords:  DMARD; Juvenile idiopathic arthritis; biologic; temporomandibular joint; uveitis

Year:  2021        PMID： 33718940      PMCID： PMC7946384          DOI： 10.12703/r/10-23

Source DB:  PubMed          Journal:  Fac Rev        ISSN： 2732-432X


  101 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

Review 2.  MicroRNAs in juvenile idiopathic arthritis: Can we learn more about pathophysiological mechanisms?

Authors:  Nadege Nziza; Isabelle Duroux-Richard; Florence Apparailly
Journal:  Autoimmun Rev       Date:  2019-06-07       Impact factor: 9.754

3.  Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.

Authors:  Ekaterina I Alexeeva; Saniya I Valieva; Tatyana M Bzarova; Elena L Semikina; Kseniya B Isaeva; Alexander O Lisitsyn; Rina V Denisova; Evgeniya G Chistyakova
Journal:  Clin Rheumatol       Date:  2011-03-08       Impact factor: 2.980

Review 4.  Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions.

Authors:  Stephanie J W Shoop-Worrall; Qiong Wu; Rebecca Davies; Kimme L Hyrich; Lucy R Wedderburn
Journal:  Lancet Child Adolesc Health       Date:  2019-07-19

5.  Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case-Control Study.

Authors:  Daniel B Horton; Frank I Scott; Kevin Haynes; Mary E Putt; Carlos D Rose; James D Lewis; Brian L Strom
Journal:  Pediatrics       Date:  2015-07-20       Impact factor: 7.124

6.  Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal.

Authors:  Jing Yao Leong; Phyllis Chen; Joo Guan Yeo; Fauziah Ally; Camillus Chua; Sharifah Nur Hazirah; Su Li Poh; Lu Pan; Liyun Lai; Elene Seck Choon Lee; Loshinidevi D/O Thana Bathi; Thaschawee Arkachaisri; Daniel Lovell; Salvatore Albani
Journal:  Ann Rheum Dis       Date:  2019-09-20       Impact factor: 19.103

7.  Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.

Authors:  Natalia Cabrera; Jean-Christophe Lega; Behrouz Kassai; Carine Wouters; Anuela Kondi; Elvira Cannizzaro; Andreas Woerner; Aurelie Chausset; Samuel Roethlisberger; Cyril Jeanneret; Florence Aeschlimann; Salma Malik; Agnès Duquesne; Daniela Kaiser; Laetitia Higel; Anne Maes; Gerald Berthet; Veronique Hentgen; Isabelle Kone-Paut; Alexandre Belot; Michael Hofer
Journal:  Joint Bone Spine       Date:  2018-09-07       Impact factor: 4.929

8.  Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.

Authors:  Ryoki Hara; Hiroaki Umebayashi; Syuji Takei; Nami Okamoto; Naomi Iwata; Yuichi Yamasaki; Yasuo Nakagishi; Toshitaka Kizawa; Ichiro Kobayashi; Tomoyuki Imagawa; Noriko Kinjo; Norihito Amano; Yoko Takahashi; Masaaki Mori; Yasuhiko Itoh; Shumpei Yokota
Journal:  Pediatr Rheumatol Online J       Date:  2019-04-30       Impact factor: 3.054

9.  Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.

Authors:  Martijn J H Doeleman; Erik M van Maarseveen; Joost F Swart
Journal:  Rheumatology (Oxford)       Date:  2019-10-01       Impact factor: 7.580

10.  The feasibility of developing biomarkers from peripheral blood mononuclear cell RNAseq data in children with juvenile idiopathic arthritis using machine learning approaches.

Authors:  Kerry E Poppenberg; Kaiyu Jiang; Lu Li; Yijun Sun; Hui Meng; Carol A Wallace; Teresa Hennon; James N Jarvis
Journal:  Arthritis Res Ther       Date:  2019-11-09       Impact factor: 5.606
View more
  1 in total

1.  Spectrum of Clinical Research in Juvenile Idiopathic Arthritis: A Cross-Sectional Analysis of Registered Studies in Clinicaltrials.gov and Clinicaltrialsregister.eu.

Authors:  Ronny Lehmann; Markus Ries
Journal:  Biomedicines       Date:  2021-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.